The drugs available against weight loss produce the best effect when used in combination with reasonable and consistent physical activity, as well as healthier eating habits.
Orlistat (Xenical), liraglutide (Saxenda) and bupropion / naltrexone (Mysimba) are indicated at obesity (BMI ≥ 30 kg / m2) and at overweight (BMI ≥ 27 kg / m2) at concomitant complication or increased cardiovascular risk.
For orlistat, there are diabetic preventive capabilities shown in the treatment of obesity with concomitant impaired glucose tolerance (IGT). Orlistat is entitled to a discount on pronounced obesity (BMI ≥ 35 kg / m2) and at BMI ≥ 28 kg / m2 for concomitant diabetes. Liraglutide and Bupropion are not included in the drug subsidy, but the patient is responsible for the entire cost of any prescription. It should be emphasized that pharmacological treatment is added as a supplement to diet and physical activity and not as a substitute for lifestyle changes.
Xenical contains as active substance orlistat. Approved indication is the treatment of obesity (BMI> 30 or BMI> 28 and other risk factors). The effect is exerted locally by inhibiting the lipases in the intestine, thereby reducing the degradation of triglycerides and decreasing the absorption of fat.